Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland.
Blood Rev. 2018 Nov;32(6):457-472. doi: 10.1016/j.blre.2018.04.003. Epub 2018 Apr 12.
T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive and heterogeneous malignancy originating from T-cell precursors. The mechanisms of T-ALL pathogenesis related to non-protein coding part of the genome are currently intensively studied. miRNAs are short, non-coding molecules acting as negative regulators of gene expression which shape phenotype of cells in a complex and context-specific manner. miRNAs may act as oncogenes or tumor suppressors; several miRNAs have been related to drug resistance and treatment response in various malignancies. Here we present the review of the state-of-the-art knowledge on the role of miRNAs in T-ALL pathogenesis, with detailed overview of the studies reporting on miRNAs with oncogenic and tumor suppressor potential. We discuss whether miRNAs might be considered candidate biomarkers of prognosis in T-ALL and leukemia subtype-specific markers. We also describe experimental approaches and a typical workflow applied in research on the involvement of miRNAs in oncogenesis.
T 细胞急性淋巴细胞白血病(T-ALL)是一种罕见的、侵袭性的和异质性的恶性肿瘤,起源于 T 细胞前体。目前正在深入研究与基因组非蛋白编码部分相关的 T-ALL 发病机制。miRNA 是短的非编码分子,作为基因表达的负调节剂,以复杂和特定于上下文的方式塑造细胞的表型。miRNA 可以作为癌基因或肿瘤抑制因子;在各种恶性肿瘤中,已经有几种 miRNA 与耐药性和治疗反应有关。在这里,我们介绍了 miRNA 在 T-ALL 发病机制中的作用的最新知识,详细介绍了报告具有致癌和肿瘤抑制潜力的 miRNA 的研究。我们讨论了 miRNA 是否可以被认为是 T-ALL 预后的候选生物标志物和白血病亚型特异性标志物。我们还描述了应用于 miRNA 参与致癌作用研究的实验方法和典型工作流程。
Adv Biol Regul. 2019-12
Oncotarget. 2016-2-16
Int J Mol Sci. 2018-9-20
Sci China C Life Sci. 2009-3
Leuk Lymphoma. 2018-9-6
Leuk Res Rep. 2025-7-10
Explor Target Antitumor Ther. 2024
Int J Mol Sci. 2022-1-13
Int J Mol Sci. 2021-5-18
Int J Mol Sci. 2021-1-15